Abstract: The present disclosure discloses a method for prolonging half-life of theanine in vivo. According to the present disclosure, a specific theanine glycoside compound formed by modification with a specific monosaccharide is used for prolonging the half-life of the theanine in vivo, which can be used for preparing sustained release drugs, prolonging action time of drugs, reducing administration frequency and improving compliance of patients. With the method of the present disclosure, the theanine glycoside compound obtained after modification can have a broad application prospect and a high commercial value in scientific research and clinical application.

Abstract: A graft copolymer and a preparation method and use thereof. The method for preparing a graft copolymer includes: dissolving an N-ethyl-2-pyrrolidinone-substituted flavan-3-ol (EPSF) and a starch in a polar organic solvent, to obtain a raw material solution; and mixing the raw material solution with ascorbic acid and hydrogen peroxide to obtain a mixture, and subjecting the mixture to a grafting reaction, to obtain the graft copolymer.

Abstract: The present disclosure discloses a method for prolonging half-life of theanine in vivo. According to the present disclosure, a specific theanine glycoside compound formed by modification with a specific monosaccharide is used for prolonging the half-life of the theanine in vivo, which can be used for preparing sustained release drugs, prolonging action time of drugs, reducing administration frequency and improving compliance of patients. With the method of the present disclosure, the theanine glycoside compound obtained after modification can have a broad application prospect and a high commercial value in scientific research and clinical application.

Abstract: The present disclosure discloses a novel strain of Glutamicibacter, derived from insects, which efficiently degrades bifenthrin, belonging to the field of microbial strains. The Glutamicibacter CCTCC NO: M20221445 of the present disclosure was isolated from the intestinal tract of bifenthrin-resistant Ectropis grisescens Warren larvae. It exhibits unique genomic characteristics, growth and phenotypic traits, physiological and biochemical characteristics, as well as the ability to utilize and degrade bifenthrin efficiently. Specifically, it can effectively degrade bifenthrin. Based on phenotypic features, physiological and biochemical characteristics, chemical composition, and molecular biology-based polyphasic classification, Glutamicibacter CCTCC NO: M20221445 is identified as a new species. This bacterium possesses the capability to efficiently degrade bifenthrin, laying the foundation for biological control of E. grisescens and offering new microbial resources to address pesticide residue problems.

Abstract: A method for determining a grade of black tea by HPLC detection belongs to the field of tea grade determination. The specific steps are as follows: adding known black tea powder samples of different grades into boiling water of 95-100° ° C. for extraction, and filtering with a filter membrane with a pore size in a range of 0.20-0.25 um to obtain black tea sample liquid; measuring contents of ten components by peak area normalization method; standardizing data of the contents of the ten components in a black tea sample solution; carrying out unsupervised principal component analysis; carrying out supervised partial least squares discriminant analysis; carrying out hierarchical clustering analysis on the basis of partial least squares discriminant analysis, and finally establishing a tea grade discrimination model based on HPLC.

Abstract: A graft copolymer and a preparation method and use thereof. The method for preparing a graft copolymer includes: dissolving an N-ethyl-2-pyrrolidinone-substituted flavan-3-ol (EPSF) and a starch in a polar organic solvent, to obtain a raw material solution; and mixing the raw material solution with ascorbic acid and hydrogen peroxide to obtain a mixture, and subjecting the mixture to a grafting reaction, to obtain the graft copolymer.

Abstract: The present disclosure discloses a novel strain of Glutamicibacter, derived from insects, which efficiently degrades bifenthrin, belonging to the field of microbial strains. The Glutamicibacter CCTCC NO: M20221445 of the present disclosure was isolated from the intestinal tract of bifenthrin-resistant Ectropis grisescens Warren larvae. It exhibits unique genomic characteristics, growth and phenotypic traits, physiological and biochemical characteristics, as well as the ability to utilize and degrade bifenthrin efficiently. Specifically, it can effectively degrade bifenthrin. Based on phenotypic features, physiological and biochemical characteristics, chemical composition, and molecular biology-based polyphasic classification, Glutamicibacter CCTCC NO: M20221445 is identified as a new species. This bacterium possesses the capability to efficiently degrade bifenthrin, laying the foundation for biological control of E. grisecens and offering new microbial resources to address pesticide residue problems.

Abstract: The present disclosure relates to the technical field of plant pests control, in particular to use of Penicillium ehrlichii Z19 in controlling plant pests, and a control method. The Penicillium ehrlichii Z19 has a deposit number of CCTCC NO: M 2021635. The Penicillium ehrlichii Z19 has a desirable insecticidal activity against lepidopteran pests, especially has a 7-day insecticidal effect of not less than 80% on Helicoverpa armigera, Plutella xylostella, Ectropis obliqua, and Spodoptera exigua. In addition, compared with traditional chemical control methods, the method for controlling pests using the Penicillium ehrlichii Z19 in the present disclosure can control the plant pests in a safe, efficient and pollution-free manner. Therefore, the method reduces pollutions to ecological environment, improves quality and safety of agricultural products, and protects human health.

Abstract: The present disclosure provides a theaflavin composition capable of promoting wound healing as well as a preparation method and use thereof. The theaflavin composition comprises theaflavin 3?-digallate or crude theaflavins as the main component; when the theaflavin composition comprises the theaflavin-3-3?-digallate as the main component, it further comprises component A or component B, or further comprises both component A and component B; when the theaflavin composition comprises the crude theaflavins as the main component, it further comprises component B, in which component A comprises sodium acetate, chitosan, and gelatin, and component B comprises glycerin, propylene glycol, triethanolamine, and Carbomer 940. The theaflavin composition provided by the present disclosure can significantly promote wound healing of diabetic mice.

Abstract: Disclosed are a tea type differentiation method and system, belonging to the technical field of detection. The method comprises: building a differentiation function by using ionic strengths of 20 compounds as evaluation indexes to discriminate tea types. According to the disclosure, the tea types are discriminated by using relative abundance of 20 compounds in tea, problems in sensory differentiation can be solved, the tea is classified more objectively and scientifically, and the reliability and accuracy of differentiation results are improved. By using three algorithms, the feasibility and accuracy of using 20 discovered compounds for tea type differentiation in a combined manner are validated.

Abstract: A method for determining a grade of black tea by HPLC detection belongs to the field of tea grade determination. The specific steps are as follows: adding known black tea powder samples of different grades into boiling water of 95-100° C. for extraction, and filtering with a filter membrane with a pore size in a range of 0.20-0.25 ?m to obtain black tea sample liquid; measuring contents of ten components by peak area normalization method; standardizing data of the contents of the ten components in a black tea sample solution; carrying out unsupervised principal component analysis; carrying out supervised partial least squares discriminant analysis; carrying out hierarchical clustering analysis on the basis of partial least squares discriminant analysis, and finally establishing a tea grade discrimination model based on HPLC. The method is simple, accurate and efficient, and whose effectiveness is not affected by the variety of black tea.

Abstract: An sDR5-Fc recombinant fusion protein having amino acid sequence of SEQ ID NO: 2 and a gene encoding the protein and having a nucleotide sequence as shown in SEQ ID NO: 1 are provided. Further, applications of the protein and the gene in the preparation of medicament for preventing and treating autoimmune hepatitis or drug-induced liver injury are provided.

Abstract: An sDR5-Fc recombinant fusion protein having amino acid sequence of SEQ ID NO: 2 and a gene encoding the protein and having a nucleotide sequence as shown in SEQ ID NO: 1 are provided. Further, applications of the protein and the gene in the preparation of medicament for preventing and treating autoimmune hepatitis or drug-induced liver injury are provided.

Abstract: The present invention provides a c-Rel-specific siRNA and its use for preventing and treating autoimmune psoriasis. In particular, the c-Rel-specific siRNAs have sequences as shown in SEQ ID Nos. 1-2 or SEQ ID Nos. 3-4. In the present invention, small interfering RNA (siRel) specific to c-Rel are employed to inhibit c-Rel biosynthesis, and prevent and treat autoimmune psoriasis by inhibiting inflammatory factors relating to IL-23/IL-17A inflammatory axis.

Abstract: The present invention provides a c-Rel-specific siRNA and its use for preventing and treating autoimmune psoriasis. In particular, the c-Rel-specific siRNAs have sequences as shown in SEQ ID Nos. 1-2 or SEQ ID Nos. 3-4. In the present invention, small interfering RNA (siRel) specific to c-Rel are employed to inhibit c-Rel biosynthesis, and prevent and treat autoimmune psoriasis by inhibiting inflammatory factors relating to IL-23/IL-17A inflammatory axis.